Here are 1-2 brief analogies for Artiva Biotherapeutics:

• The Henry Ford of cell therapies: Artiva aims to mass-produce and make widely accessible advanced treatments for autoimmune diseases and cancers that are currently bespoke and expensive, like personalized CAR-T cell therapies.
• The Southwest Airlines of cell therapies: Artiva is developing more scalable, accessible, and cost-effective "off-the-shelf" cell therapies compared to the highly personalized and complex CAR-T treatments offered by companies like Novartis or Gilead.

• AlloNK: A non-genetically modified, cryopreserved, allogeneic, off-the-shelf natural killer (NK) cell therapy candidate being developed for autoimmune diseases and B-cell non-Hodgkin lymphoma.

Artiva Biotherapeutics (ARTV) is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Their product candidates, such as AlloNK, are currently in various phases of clinical trials and have not yet received regulatory approval for commercial sale. As such, Artiva Biotherapeutics does not currently have major customers that purchase its products or services in the market.

The company is focused on research and development and advancing its product candidates through clinical trials. Therefore, it does not sell primarily to other companies or individuals at this stage.

Fred Aslan, M.D., President and Chief Executive Officer

Fred Aslan joined Artiva Biotherapeutics as CEO in January 2021, bringing over two decades of experience as an executive and investor in the life sciences industry. Previously, he served as President and Chief Business Officer at Vividion Therapeutics, which was acquired by Bayer. During his tenure at Vividion, he was responsible for business development, finance, and operations, and led the company's Series B financing and a significant collaboration with Roche. Dr. Aslan also has a 12-year affiliation with Venrock, a venture capital firm, where he co-founded and served on the board of Receptos Pharmaceuticals, which was acquired by Celgene for over $7 billion. He also led Venrock's investment in Zeltiq, acquired by Allergan for more than $2 billion. Furthermore, he founded and served as CEO of Adavium Medical, a Brazilian medical device company, growing it to 350 employees and over $40 million in sales. His earlier career included roles as Director of Business Development and Head of Investor Relations for CuraGen, and a consultant at Boston Consulting Group.

Thad Huston, Chief Financial Officer

Thad Huston was appointed Chief Financial Officer of Artiva Biotherapeutics in February 2026. He possesses over 30 years of global leadership experience across finance, commercial strategy, business development, and operations within public companies in the pharmaceuticals, biotechnology, and medical device sectors. Most recently, he served as Chief Financial Officer and Chief Operating Officer at Galapagos NV from July 2023 to August 2025, where he oversaw finance, commercial, operations, quality, IT, and business development. Prior to Galapagos, Mr. Huston was the Global Head of Finance and Corporate Operations at Kite Pharma (a Gilead Company) from 2021 to 2023, where he managed finance and IT and spearheaded strategic planning and operational initiatives. His experience also includes serving as CFO of LivaNova, a publicly listed medical devices company, and holding senior financial leadership roles at Johnson & Johnson for over 25 years.

Jennifer Bush, Chief Operating Officer

Jennifer Bush serves as the Chief Operating Officer of Artiva Biotherapeutics, where she leads legal, people and culture, information technology, patient engagement, and community access initiatives. She joined Artiva in 2020 as General Counsel, becoming Chief Legal & People Officer in 2021, and then Chief Operating Officer in April 2024. Before her time at Artiva, Ms. Bush was the Senior Vice President and General Counsel of Organovo, Inc., a tissue engineering company, responsible for its legal, human resources, regulatory, and government relations functions. She also held a senior legal position at Broadcom. Ms. Bush began her career as a commercial and intellectual property litigator at Fish & Richardson, representing life science, medical device, and software companies for a decade.

Subhashis Banerjee, M.D., Chief Medical Officer

Dr. Subhashis Banerjee was appointed Chief Medical Officer of Artiva Biotherapeutics in April 2025. He is a trained rheumatologist and immunologist with over two decades of clinical development experience in autoimmune diseases. Before joining Artiva, Dr. Banerjee was the Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), where he played a key role in immunology asset development. He also served as Senior Vice President of Clinical Development at VYNE Therapeutics Inc., leading clinical development of BET inhibitors. Dr. Banerjee's extensive background includes supporting the clinical development of Xeljanz® at Pfizer Inc., early development activities of Humira® at AbbVie, and leading clinical programs for Taltz® at Eli Lilly and Company.

Christopher Horan, Chief Technical Operations Officer

Christopher Horan is the Chief Technical Operations Officer at Artiva Biotherapeutics, overseeing CMC development, manufacturing, supply chain, and quality. Prior to Artiva, he spent nearly 14 years at Genentech, a member of the Roche Group, where he held several leadership positions in technical operations, including Senior Vice President, Global Product and Supply Chain Management for Roche in Switzerland, leading a 480-person team responsible for global biopharma product supply. He also served as Chief Technical Officer (CTO) at SanBio, where he managed process development, manufacturing, supply, and quality systems. Before SanBio, Mr. Horan was CTO at Dermira, leading pharmaceutical sciences, manufacturing, quality, supply chain, and procurement, and was instrumental in supporting the company's acquisition by Eli Lilly and Company. He began his career at Merck & Co. with over a decade of increasing responsibility in technical operations.

1. Failure to successfully complete clinical development and obtain regulatory approval for AlloNK or other product candidates. As a clinical-stage biotechnology company, Artiva Biotherapeutics' valuation is highly sensitive to the outcomes of its clinical trials and regulatory decisions. The company explicitly states that it will take several years before it completes clinical development and receives regulatory approval for AlloNK or any of its product candidates, if at all. Receiving special designations, such as Fast Track designation, does not guarantee an accelerated review or increase the likelihood of FDA approval. Clinical trials are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome.
2. Inability to secure adequate additional funding to support ongoing operations and development. Artiva Biotherapeutics has no approved products and does not yet generate revenues from product sales, making the need for substantial additional capital a significant risk. The company reported a net loss of $83.9 million in 2025 and estimates its current cash position will fund operations only into the second quarter of 2027. If unable to secure adequate capital, Artiva may be forced to delay, reduce, or eliminate its research and development programs, which could significantly impact shareholder value and its ability to continue as a going concern.
3. Inability to successfully compete with existing or emerging treatments in the autoimmune disease market. The global market for autoimmune disease treatments reached approximately $160 billion in 2023, indicating a highly competitive landscape with various approved therapies already available. While Artiva aims to differentiate AlloNK based on scalability, safety, and cost advantages over autologous CAR-T cell therapies, the current clinical data for NK cell therapies in autoimmune diseases is limited, raising uncertainties about their therapeutic benefits and competitiveness against established treatments. Artiva faces competition from various pharmaceutical companies developing therapies in the "pharmaceutical products" industry.

Here are 3 expected drivers of future revenue growth for Artiva Biotherapeutics (ARTV) over the next 2-3 years:

1. Achievement of Positive Clinical Trial Data for AlloNK in Autoimmune Diseases: Artiva Biotherapeutics' lead product candidate, AlloNK, is currently in Phase 1/1b and basket investigator-initiated trials for various autoimmune indications, including systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), rheumatoid arthritis (RA), pemphigus vulgaris (PV), and ANCA-associated vasculitis (AAV). Positive and compelling data readouts from these ongoing and future clinical trials, demonstrating AlloNK's ability to drive deep B-cell depletion and achieve favorable clinical responses, would significantly de-risk the asset. This validation is expected to enhance AlloNK's attractiveness to potential strategic partners and collaborators, leading to revenue generation through upfront payments and milestone achievements tied to development progress.
2. Establishment of New Strategic Collaborations and Licensing Agreements: As a clinical-stage biotechnology company with product approval "several years" away, Artiva's near-term revenue growth is anticipated to be driven by partnerships. AlloNK's "off-the-shelf" nature, scalability, improved safety profile (lower rates of ICANS and CRS compared to auto-CAR-T), and potentially lower cost of goods sold (COGS) present strong advantages that are likely to attract larger pharmaceutical companies seeking to expand their autoimmune disease portfolios. Securing new collaboration or licensing agreements for AlloNK, especially leveraging its "first mover advantages" in autoimmune diseases, would provide crucial upfront payments and milestone-based revenue streams.
3. Expansion of AlloNK's Clinical Pipeline and Indications: Artiva is actively exploring AlloNK across a range of autoimmune diseases beyond SLE/LN through its basket investigator-initiated trial (IIT). Continued successful advancement of AlloNK through IND clearances and into further clinical development for additional high-unmet-need autoimmune conditions, such as RA, PV, and AAV subtypes, would broaden the product candidate's potential market reach. This strategic expansion of the pipeline is expected to increase the overall value and commercial appeal of AlloNK, potentially leading to more comprehensive and lucrative partnership opportunities or expansion of existing collaborations, thereby contributing to revenue growth.

Share Issuance

• Artiva Biotherapeutics experienced a significant increase in shares outstanding by 354.77% in one year, which is likely related to its IPO in July 2024 and subsequent capital raises.
• An at-the-market (ATM) equity program was established to provide additional financing flexibility, authorizing the potential to raise up to $11.95 million, though this program remained unused as of March 10, 2026.

Capital Expenditures

• Capital expenditures amounted to -$2.23 million in the last 12 months (up to early 2026).
• In Q4 2025, the company invested $421,000 in capital expenditures to fund long-term assets and infrastructure.
• The primary focus of capital expenditures included expanding cGMP manufacturing capacity through a partnership with GC Cell and investments in an in-house San Diego facility, as well as enhancing cold chain logistics for product distribution.